| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
others
3-Indolyl-β-D-glucuronide targets the enzyme β-D-glucuronidase, which is produced by E. coli and other bacteria. It serves as a substrate for this enzyme, and its cleavage results in the formation of a blue precipitate. Its "target" is β-D-glucuronidase activity, making it a useful tool for microbial detection. |
|---|---|
| ln Vitro |
In vitro, 3-Indolyl-β-D-glucuronide is used as a chromogenic substrate for β-D-glucuronidase to detect and enumerate E. coli in microbiological samples. The cleavage of the substrate produces a blue precipitate, allowing for visual detection. Its activity is measured by the appearance of color, which correlates with enzyme activity and bacterial presence.
|
| ln Vivo |
In vivo, 3-Indolyl-β-D-glucuronide is not administered as a therapeutic agent. However, its presence in patient plasma can serve as a new indicator of renal failure. It is a biochemical marker that reflects the activity of β-D-glucuronidase or the accumulation of glucuronide metabolites.
|
| Enzyme Assay |
In vitro enzyme assays with 3-Indolyl-β-D-glucuronide typically involve measuring β-D-glucuronidase activity. The substrate is incubated with enzyme preparations or bacterial cultures in appropriate buffer, and the release of the chromogenic product (indigo) is monitored by spectrophotometry at a specific wavelength. The intensity of the color is proportional to enzyme activity.
|
| Cell Assay |
3-Indolyl-β-D-glucuronide is not typically used in cell culture experiments as a bioactive compound for treating mammalian cells. However, it may be used to detect β-D-glucuronidase activity in cell lysates or to monitor bacterial contamination in cell culture. Its primary use is in microbiological detection.
|
| Animal Protocol |
In vivo animal experiments with 3-Indolyl-β-D-glucuronide are not commonly performed. However, it may be used in studies of renal function, as its presence in patient plasma can indicate renal failure. Its utility lies in its role as a diagnostic marker rather than as a therapeutic agent.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Uremic toxins often accumulate in the blood due to overeating or poor kidney filtration. Most uremic toxins are metabolic waste products that are normally excreted through urine or feces. The pharmacokinetic (PK) properties of 3-Indolyl-β-D-glucuronide are not well characterized. As a glucuronide conjugate, it may be formed in the liver and excreted in urine. Its presence in plasma reflects the balance between formation and clearance, and elevated levels may indicate renal dysfunction. |
| Toxicity/Toxicokinetics |
Toxicity Summary
Uremic toxins, such as indole-β-D-glucuronide, can be actively transported to the kidneys via organic ion transporters, particularly OAT3. Elevated uremic toxin levels can stimulate the production of reactive oxygen species (ROS). This appears to be mediated by the direct binding of uremic toxins to or inhibition of NADPH oxidases, particularly NOX4, which is abundant in the kidneys and heart (A7868). ROS can induce a variety of different DNA methyltransferases (DNMTs) involved in the silencing of the KLOTHO protein. KLOTHO has been shown to play an important role in anti-aging, mineral metabolism, and vitamin D metabolism. Multiple studies have shown that in acute or chronic kidney disease, KLOTHO mRNA and protein levels are decreased due to elevated local ROS levels (A7869). 3-Indolyl-β-D-glucuronide has a low toxicity profile as a research reagent. For research use, standard laboratory safety practices are sufficient. It is not considered a hazardous substance. It is typically stored as a solid and handled according to standard laboratory protocols. |
| References | |
| Additional Infomation |
Indoleglucuronic acid is a type of glucuronic acid. Indoleglucuronic acid is a uremic toxin. Uremic toxins can be classified into three main categories based on their chemical and physical properties: 1) small, water-soluble, non-protein-bound compounds, such as urea; 2) small, lipid-soluble and/or protein-bound compounds, such as phenols; and 3) larger, so-called medium-molecule compounds, such as β2-microglobulins. Long-term exposure to uremic toxins can lead to various diseases, including kidney damage, chronic kidney disease, and cardiovascular disease. Indoleglucuronic acid is a natural human metabolite produced in the liver by UDP-glucuronyltransferase from indole. Glucuronization helps eliminate toxic substances, drugs, or other substances that cannot be used as an energy source. Glucuronic acid is linked to this substance via a glycosidic bond, and the resulting glucuronide is much more water-soluble than the original substance and is ultimately excreted through the kidneys.
3-Indolyl-β-D-glucuronide is a chromogenic substrate for β-D-glucuronidase used for the detection and enumeration of E. coli in microbiological samples. Cleavage produces a blue precipitate. Its presence in patient plasma can serve as a new indicator of renal failure. The compound is not a drug and has no therapeutic indications. |
| Molecular Formula |
C14H15NO7
|
|---|---|
| Molecular Weight |
309.27
|
| Exact Mass |
309.084
|
| CAS # |
35804-66-1
|
| PubChem CID |
2733785
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
669.0±55.0 °C at 760 mmHg
|
| Flash Point |
358.4±31.5 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.746
|
| LogP |
-0.91
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
420
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
OC(C1OC(OC2=CNC3=CC=CC=C23)C(O)C(O)C1O)=O
|
| InChi Key |
KUYNOZVWCFXSNE-BYNIDDHOSA-N
|
| InChi Code |
InChI=1S/C14H15NO7/c16-9-10(17)12(13(19)20)22-14(11(9)18)21-8-5-15-7-4-2-1-3-6(7)8/h1-5,9-12,14-18H,(H,19,20)/t9-,10-,11+,12-,14+/m0/s1
|
| Chemical Name |
(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(1H-indol-3-yloxy)oxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2334 mL | 16.1671 mL | 32.3342 mL | |
| 5 mM | 0.6467 mL | 3.2334 mL | 6.4668 mL | |
| 10 mM | 0.3233 mL | 1.6167 mL | 3.2334 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
